Go Pro
→ Gates. Google. The Pentagon. (From Behind the Markets) (Ad)tc pixel Free CTMX Stock Alerts

CytomX Therapeutics (CTMX) Financials

CytomX Therapeutics logo
$3.70 -0.06 (-1.60%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$3.75 +0.05 (+1.35%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CytomX Therapeutics

Annual Income Statements for CytomX Therapeutics

This table shows CytomX Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -42 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -20
Consolidated Net Income / (Loss)		 -35 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -17
Net Income / (Loss) Continuing Operations		 -35 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -17
Total Pre-Tax Income 		-35 -59 -44 -70 -133 -79 -116 -99 3.32 32 -17
Total Operating Income		 -33 -60 -46 -78 -141 -81 -116 -101 -6.48 25 -22
Total Gross Profit		 7.71 15 72 60 27 68 37 53 101 138 76
Total Revenue		 7.71 15 72 60 27 68 37 53 101 138 76
Operating Revenue		 7.71 15 72 60 27 68 37 53 101 138 76
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 41 75 118 137 168 149 153 154 108 113 99
Selling, General & Admin Expense		 13 20 26 34 37 36 39 43 30 30 30
Research & Development Expense		 28 55 92 104 132 113 114 112 78 83 69
Total Other Income / (Expense), net		 -2.16 0.67 2.65 7.57 8.23 1.81 0.17 2.02 9.81 7.10 5.23
Interest & Investment Income		 1.32 0.74 2.67 7.64 8.37 1.84 0.26 1.68 9.84 7.14 5.21
Other Income / (Expense), net		 -1.74 -0.07 -0.03 -0.07 -0.14 -0.03 -0.08 0.34 -0.03 -0.04 0.03
Income Tax Expense		 0.01 -0.02 -0.51 14 -0.43 -14 0.00 0.00 3.89 0.22 0.24
Basic Earnings per Share		 ($4.90) ($1.63) ($1.16) - ($2.93) ($1.40) ($1.81) ($1.51) ($0.01) $0.38 ($0.15)
Weighted Average Basic Shares Outstanding		 8.60M 36.23M 37.17M 41.66M 45.34M 46.15M 64.15M 65.74M 73.81M 84.44M 137.94M
Diluted Earnings per Share		 ($4.90) ($1.63) ($1.16) - ($2.93) ($1.40) ($1.81) ($1.51) ($0.01) $0.38 ($0.15)
Weighted Average Diluted Shares Outstanding		 8.60M 36.23M 37.17M 41.66M 45.34M 46.15M 64.15M 65.74M 73.81M 84.75M 137.94M
Weighted Average Basic & Diluted Shares Outstanding		 8.60M 36.23M 37.17M 41.66M 45.34M 46.15M 65.39M 66.23M 67.72M 80.10M 170.19M

Quarterly Income Statements for CytomX Therapeutics

This table shows CytomX Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 2.99 0.84 14 -6.53 5.74 19 24 -0.15 -14 -30 -18
Consolidated Net Income / (Loss)		 2.99 0.84 14 -6.53 5.74 19 24 -0.15 -14 -27 -18
Net Income / (Loss) Continuing Operations		 2.99 0.84 14 -6.53 5.74 19 24 -0.15 -14 -27 -18
Total Pre-Tax Income 		5.82 1.91 14 -6.48 5.80 19 24 -0.09 -14 -26 -18
Total Operating Income		 3.12 -0.61 12 -8.45 4.11 18 23 -1.29 -16 -28 -20
Total Gross Profit		 26 27 41 25 33 38 51 19 5.96 0.66 10
Total Revenue		 26 27 41 25 33 38 51 19 5.96 0.66 10
Operating Revenue		 26 27 41 25 33 38 51 19 5.96 0.66 10
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 23 27 30 34 29 20 28 20 22 29 30
Selling, General & Admin Expense		 6.81 7.83 7.75 8.40 7.95 5.62 9.43 6.62 6.43 7.36 11
Research & Development Expense		 16 19 22 25 21 15 19 13 15 21 19
Total Other Income / (Expense), net		 2.69 2.51 2.18 1.97 1.69 1.26 0.97 1.20 1.60 1.48 1.48
Interest & Investment Income		 2.70 2.50 2.19 1.97 1.69 1.28 0.96 1.18 1.59 1.48 1.49
Other Income / (Expense), net		 -0.01 0.01 -0.01 -0.00 -0.01 -0.02 0.01 0.02 0.01 -0.01 -0.01
Income Tax Expense		 2.82 1.07 0.05 0.05 0.06 0.06 0.06 0.06 0.06 0.06 0.06
Weighted Average Basic Shares Outstanding		 80.73M 73.81M 82.03M 84.88M 85.09M 84.44M 87.12M 129.08M 165.00M 137.94M 177.27M
Weighted Average Diluted Shares Outstanding		 80.99M 73.81M 82.63M 84.88M 85.20M 84.75M 87.15M 129.08M 165.00M 137.94M 177.27M
Weighted Average Basic & Diluted Shares Outstanding		 66.99M 67.72M - 78.12M 78.26M 80.10M 80.62M 164.91M 169.44M 170.19M 217.70M

Annual Cash Flow Statements for CytomX Therapeutics

This table details how cash moves in and out of CytomX Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -4.57 45 73 70 -59 3.43 14 -12 -176 21 -25
Net Cash From Operating Activities		 -29 -2.03 170 -76 -140 5.26 -119 -111 -56 -86 -76
Net Cash From Continuing Operating Activities		 -27 -2.03 170 -76 -140 5.26 -119 -111 -56 -86 -76
Net Income / (Loss) Continuing Operations		 -35 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -17
Consolidated Net Income / (Loss)		 -35 -59 -43 -85 -133 -65 -116 -99 -0.57 32 -17
Depreciation Expense		 -1.21 1.73 1.52 1.74 2.46 2.43 2.56 2.30 2.03 1.62 1.23
Amortization Expense		 1.11 1.66 0.52 -1.56 -2.08 -0.09 0.42 0.09 -7.27 -5.17 -2.06
Non-Cash Adjustments To Reconcile Net Income		 -0.79 14 212 17 23 18 16 17 12 12 11
Changes in Operating Assets and Liabilities, net		 8.85 39 -0.46 -7.98 -31 50 -22 -31 -63 -126 -69
Net Cash From Investing Activities		 -131 46 -121 5.93 80 -19 22 98 -151 100 -60
Net Cash From Continuing Investing Activities		 -131 46 -121 5.93 80 -19 22 98 -151 100 -60
Purchase of Property, Plant & Equipment		 -1.59 -2.18 -1.56 -3.79 -3.50 -2.31 -1.61 -1.74 -0.84 -0.31 -0.22
Purchase of Investments		 -251 -122 -219 -205 -175 -199 -100 0.00 -425 -155 -193
Sale and/or Maturity of Investments		 123 170 99 214 258 183 124 100 275 256 133
Net Cash From Financing Activities		 153 1.00 24 140 1.63 17 110 0.65 30 7.52 110
Net Cash From Continuing Financing Activities		 153 1.00 24 140 1.63 17 110 0.65 30 7.52 110
Issuance of Common Equity		 82 0.93 24 140 1.63 17 110 0.65 30 7.52 110

Quarterly Cash Flow Statements for CytomX Therapeutics

This table details how cash moves in and out of CytomX Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -32 -8.85 19 7.06 -2.56 -2.52 9.55 1.44 -15 -21 16
Net Cash From Operating Activities		 -18 -22 -26 -20 -21 -20 -21 -16 -16 -23 -26
Net Cash From Continuing Operating Activities		 -18 -22 -26 -20 -21 -20 -21 -16 -16 -23 -26
Net Income / (Loss) Continuing Operations		 2.99 0.84 14 -6.53 5.74 19 24 -0.15 -14 -27 -18
Consolidated Net Income / (Loss)		 2.99 0.84 14 -6.53 5.74 19 24 -0.15 -14 -27 -18
Depreciation Expense		 0.45 0.45 0.43 0.42 0.39 0.38 0.35 0.31 0.10 0.47 0.21
Amortization Expense		 -1.90 -2.19 -1.83 -1.40 -1.18 -0.75 -0.42 -0.36 -0.60 -0.68 -0.69
Non-Cash Adjustments To Reconcile Net Income		 2.17 3.52 2.89 2.89 3.03 3.05 3.09 2.54 2.52 3.04 5.84
Changes in Operating Assets and Liabilities, net		 -22 -25 -41 -15 -29 -41 -48 -18 -3.33 0.43 -13
Net Cash From Investing Activities		 -43 13 45 22 18 15 31 -76 0.44 -14 -193
Net Cash From Continuing Investing Activities		 -43 13 45 22 18 15 31 -76 0.44 -14 -193
Purchase of Property, Plant & Equipment		 -0.01 -0.27 -0.12 -0.10 -0.02 -0.08 -0.12 -0.03 0.13 -0.20 0.00
Purchase of Investments		 -93 -112 0.00 -93 -12 -50 -20 -109 -20 -44 -243
Sale and/or Maturity of Investments		 50 125 45 115 31 65 51 33 20 30 50
Net Cash From Financing Activities		 30 0.24 0.17 5.10 - 2.25 0.00 94 0.25 17 234
Net Cash From Continuing Financing Activities		 30 0.24 0.17 5.10 - 2.25 0.00 94 0.25 17 234
Issuance of Common Equity		 30 0.24 0.17 5.10 - 2.25 0.00 94 0.25 17 234

Annual Balance Sheets for CytomX Therapeutics

This table presents CytomX Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 197 199 398 457 341 359 339 261 202 121 152
Total Current Assets		 190 188 389 445 303 324 310 237 183 107 144
Cash & Equivalents		 60 105 178 248 188 192 206 194 17 38 13
Short-Term Investments		 127 77 197 189 108 124 100 0.00 157 63 124
Accounts Receivable		 0.74 2.31 10 0.10 0.01 0.80 0.79 36 3.43 3.10 2.01
Prepaid Expenses		 2.30 3.90 4.35 9.25 7.18 7.10 4.29 7.47 5.00 3.58 4.86
Plant, Property, & Equipment, net		 3.48 4.39 4.22 6.93 7.37 6.95 5.96 5.07 3.96 2.47 1.30
Total Noncurrent Assets		 3.98 6.59 4.83 4.70 31 28 23 19 15 11 6.34
Goodwill		 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95
Intangible Assets		 1.75 1.75 1.60 1.46 1.31 1.17 1.02 0.88 0.73 0.58 0.44
Other Noncurrent Operating Assets		 0.36 3.89 2.27 2.29 28 26 21 17 13 9.23 4.95
Total Liabilities & Shareholders' Equity		 197 199 398 457 341 359 339 261 202 121 152
Total Liabilities		 71 121 328 326 290 366 340 347 249 121 53
Total Current Liabilities		 16 36 61 98 86 68 78 153 156 86 47
Accounts Payable		 4.70 6.60 4.21 5.13 4.16 3.00 2.82 2.81 1.46 1.09 1.30
Accrued Expenses		 4.91 8.82 16 27 30 23 34 24 18 12 14
Current Deferred Revenue		 6.13 20 41 53 51 42 41 121 132 67 27
Other Current Liabilities		 - - - - - - - 4.08 4.59 5.15 4.24
Total Noncurrent Liabilities		 55 85 267 228 205 298 262 194 93 35 5.94
Noncurrent Deferred Revenue		 55 84 265 225 179 277 244 180 80 27 1.59
Other Noncurrent Operating Liabilities		 0.20 0.57 1.90 3.05 0.85 - - 0.00 3.89 4.12 4.35
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 126 78 70 131 51 -7.77 -0.46 -86 -47 -0.46 99
Total Preferred & Common Equity		 126 78 70 131 51 -7.77 -0.46 -86 -47 -0.46 99
Preferred Stock		 - 0.00 - - 0.00 - - 0.00 0.00 0.00 0.00
Total Common Equity		 126 78 70 131 51 -7.77 -0.46 -86 -47 -0.46 99
Common Stock		 244 255 289 446 468 500 623 637 676 691 811
Retained Earnings		 -117 -176 -219 -315 -417 -508 -624 -723 -723 -692 -712
Accumulated Other Comprehensive Income / (Loss)		 -0.08 -0.03 -0.09 -0.09 0.06 -0.05 -0.24 0.01 0.10 0.03 0.11

Quarterly Balance Sheets for CytomX Therapeutics

This table presents CytomX Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 209 221 185 159 139 98 175 158 359
Total Current Assets		 188 201 167 143 124 87 165 149 353
Cash & Equivalents		 58 26 36 43 41 48 49 34 29
Short-Term Investments		 123 168 114 94 77 32 109 109 318
Accounts Receivable		 1.90 2.42 13 2.78 3.35 1.96 1.87 1.63 0.65
Prepaid Expenses		 5.04 4.68 3.79 3.12 3.24 4.79 4.67 3.96 5.74
Plant, Property, & Equipment, net		 4.50 4.06 3.57 3.32 2.94 2.23 1.95 1.72 1.09
Total Noncurrent Assets		 17 16 14 13 12 9.64 8.49 7.32 5.17
Goodwill		 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95
Intangible Assets		 0.80 0.77 0.69 0.66 0.62 0.55 0.51 0.47 0.40
Other Noncurrent Operating Assets		 15 14 12 11 10 8.14 7.03 5.89 3.82
Total Liabilities & Shareholders' Equity		 209 221 185 159 139 98 175 158 359
Total Liabilities		 294 272 216 190 162 73 55 51 39
Total Current Liabilities		 141 147 145 143 119 50 39 41 34
Accounts Payable		 1.03 1.71 1.96 0.61 1.42 0.28 0.23 0.65 1.37
Accrued Expenses		 20 21 14 14 17 11 12 12 12
Current Deferred Revenue		 120 124 124 124 96 33 22 22 18
Other Current Liabilities		 - - 4.72 4.86 5.00 5.29 5.44 5.60 2.86
Total Noncurrent Liabilities		 153 126 72 48 43 23 16 9.84 5.39
Noncurrent Deferred Revenue		 141 112 60 37 34 16 10 5.54 0.98
Other Noncurrent Operating Liabilities		 0.22 2.76 3.94 3.99 4.05 4.18 4.24 4.30 4.41
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -85 -51 -32 -31 -23 25 120 107 320
Total Preferred & Common Equity		 -85 -51 -32 -31 -23 25 120 107 320
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -85 -51 -32 -31 -23 25 120 107 320
Common Stock		 642 673 678 685 687 693 788 790 1,050
Retained Earnings		 -727 -724 -710 -716 -710 -668 -668 -682 -730
Accumulated Other Comprehensive Income / (Loss)		 0.04 -0.06 -0.01 -0.00 0.04 -0.00 0.03 0.10 0.10

Annual Metrics And Ratios for CytomX Therapeutics

This table displays calculated financial ratios and metrics derived from CytomX Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 36,024,292.00 36,402,346.00 38,408,626.00 45,007,104.00 45,434,164.00 46,224,402.00 65,249,116.00 66,084,367.00 66,988,904.00 78,258,879.00 170,186,742.00
DEI Adjusted Shares Outstanding		 36,024,292.00 36,402,346.00 38,408,626.00 45,007,104.00 45,434,164.00 46,224,402.00 65,249,116.00 66,084,367.00 66,988,904.00 78,258,879.00 170,186,742.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.17 -1.62 -1.12 -1.88 -2.92 -1.40 -1.78 -1.50 -0.01 0.41 -0.12
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -23 -42 -32 -55 -99 -56 -81 -71 1.11 25 -16
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -2.92% 655.93% -15.81%
Earnings before Interest and Taxes (EBIT)		 -35 -60 -46 -78 -142 -81 -116 -101 -6.51 25 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -35 -56 -44 -78 -141 -78 -113 -99 -12 21 -23
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 0.19 168 -53 -184 26 -96 -93 -52 -91 -74
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -62 -103 -304 -305 -220 -302 -288 -265 -213 -97 -38
Increase / (Decrease) in Invested Capital		 1.78 -42 -201 -1.03 85 -82 15 22 53 116 59
Book Value per Share		 $3.50 $2.16 $1.82 $2.91 $1.13 ($0.17) ($0.01) ($1.30) ($0.71) ($0.01) $0.58
Tangible Book Value per Share		 $3.42 $2.08 $1.75 $2.85 $1.08 ($0.21) ($0.04) ($1.33) ($0.73) ($0.03) $0.58
Total Capital		 126 78 70 131 76 14 18 -72 -38 3.78 99
Total Debt		 0.00 0.00 0.00 0.00 25 22 18 14 9.39 4.24 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 25 22 18 14 9.39 4.24 0.00
Net Debt		 -187 -182 -374 -436 -271 -294 -287 -180 -165 -96 -137
Capital Expenditures (CapEx)		 1.59 2.12 1.56 3.79 3.50 2.31 1.61 1.74 0.84 0.31 0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -30 -47 -89 -78 -60 -73 -109 -147 -79 -40
Debt-free Net Working Capital (DFNWC)		 174 152 327 348 218 256 232 84 27 22 97
Net Working Capital (NWC)		 174 152 327 348 218 256 232 84 27 22 97
Net Nonoperating Expense (NNE)		 12 17 11 30 34 8.44 35 28 1.68 -7.05 1.71
Net Nonoperating Obligations (NNO)		 -188 -182 -374 -436 -271 -294 -287 -180 -165 -96 -137
Total Depreciation and Amortization (D&A)		 -0.10 3.40 2.03 0.18 0.38 2.34 2.98 2.39 -5.24 -3.54 -0.83
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.16) ($2.03) ($2.26) $0.00 ($1.30) $0.00 ($0.01) $0.38 ($0.15)
Adjusted Weighted Average Basic Shares Outstanding		 36.08M 36.52M 38.61M 45.11M 45.57M 64.78M 65.39M 0.00 73.81M 84.44M 137.94M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.16) ($2.03) ($2.26) $0.00 ($1.30) $0.00 ($0.01) $0.38 ($0.15)
Adjusted Weighted Average Diluted Shares Outstanding		 36.08M 36.52M 38.61M 45.11M 45.57M 64.78M 65.39M 0.00 73.81M 84.75M 137.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.16) ($2.03) ($2.26) $0.00 ($1.30) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.60M 36.23M 37.17M 41.66M 45.34M 46.15M 64.15M 0.00 67.72M 80.10M 170.19M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -42 -32 -55 -99 -56 -81 -71 -4.54 25 -16
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for CytomX Therapeutics

This table displays calculated financial ratios and metrics derived from CytomX Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 66,767,779.00 66,988,904.00 67,721,658.00 67,721,658.00 78,117,601.00 78,258,879.00 80,099,889.00 80,621,293.00 164,912,906.00 170,186,742.00 170,186,742.00
DEI Adjusted Shares Outstanding		 66,767,779.00 66,988,904.00 67,721,658.00 67,721,658.00 78,117,601.00 78,258,879.00 80,099,889.00 80,621,293.00 164,912,906.00 170,186,742.00 170,186,742.00
DEI Earnings Per Adjusted Shares Outstanding		 0.04 0.01 0.20 -0.10 0.07 0.24 0.29 0.00 -0.09 -0.17 -0.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 136.69% 32.22% 76.45% 1.58% 26.71% 43.17% 22.80% -25.71% -82.16% - -79.85%
EBITDA Growth		 105.73% 73.76% 255.78% -109.16% 98.74% 839.71% 120.19% 86.02% -590.94% - -189.32%
EBIT Growth		 110.50% 93.72% 306.56% -149.01% 31.71% 3,058.29% 94.33% 84.99% -484.09% - -186.95%
NOPAT Growth		 107.73% 96.00% 393.54% -152.45% 153.15% 6,721.18% 94.23% 84.78% -371.34% - -161.03%
Net Income Growth		 110.29% 109.54% 516.52% -501.10% 91.71% 2,155.20% 70.58% 97.64% -348.06% - -177.57%
EPS Growth		 109.09% 115.38% 440.00% -300.00% 75.00% 1,000.00% 58.82% 100.00% -228.57% - 0.00%
Operating Cash Flow Growth		 46.10% -1,476.67% -378.59% 22.36% -13.63% 9.36% 19.21% 19.42% 24.99% - -21.41%
Free Cash Flow Firm Growth		 190.46% -84.07% -195.66% -211.44% -211.26% -84.69% -6.94% -27.56% -15.76% - 60.73%
Invested Capital Growth		 -55.71% 19.91% 37.54% 36.44% 42.30% 54.44% 70.09% 77.26% 73.25% - 48.51%
Revenue Q/Q Growth		 6.71% 0.85% 55.83% -39.43% 33.12% 13.94% 33.67% -63.36% -68.04% - 1,447.21%
EBITDA Q/Q Growth		 136.96% -240.19% 538.47% -192.06% 135.12% 421.79% 30.52% -105.85% -1,133.13% - 28.39%
EBIT Q/Q Growth		 191.78% -119.16% 2,050.75% -172.59% 148.55% 330.34% 28.15% -105.61% -1,142.16% - 29.56%
NOPAT Q/Q Growth		 168.56% -116.56% 4,464.87% -150.93% 168.75% 333.17% 28.04% -103.99% -1,126.13% - 29.57%
Net Income Q/Q Growth		 375.25% -72.03% 1,547.67% -147.38% 187.79% 229.08% 24.63% -100.65% -9,139.61% - 31.17%
EPS Q/Q Growth		 300.00% -50.00% 750.00% -147.06% 187.50% 214.29% 22.73% -100.00% 0.00% - 0.00%
Operating Cash Flow Q/Q Growth		 27.54% -20.39% -18.59% 24.94% -6.04% 3.96% -5.70% 25.14% 1.30% - -9.92%
Free Cash Flow Firm Q/Q Growth		 -3.19% -162.06% -74.76% -6.14% 3.34% -3.02% -1.18% -26.61% 12.29% - 50.24%
Invested Capital Q/Q Growth		 7.63% 9.45% 18.23% 7.07% 16.15% 28.50% 46.32% 29.33% 1.36% - 29.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 6.32% -8.78% 24.71% -37.56% 9.91% 45.38% 44.31% -7.07% -272.77% - -196.47%
Operating Margin		 11.84% -2.28% 28.11% -33.65% 12.30% 46.41% 44.43% -6.89% -264.43% - -191.77%
EBIT Margin		 11.81% -2.24% 28.09% -33.66% 12.28% 46.36% 44.45% -6.80% -264.35% - -191.84%
Profit (Net Income) Margin		 11.34% 3.15% 33.26% -26.02% 17.16% 49.55% 46.20% -0.83% -238.62% - -177.89%
Tax Burden Percent		 51.45% 43.91% 99.65% 100.79% 98.95% 99.67% 99.74% 169.23% 100.41% - 100.32%
Interest Burden Percent		 186.62% -319.26% 118.84% 76.69% 141.25% 107.24% 104.22% 7.17% 89.90% - 92.43%
Effective Tax Rate		 48.55% 56.09% 0.35% 0.00% 1.05% 0.33% 0.26% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 89.46% 0.85% -27.95% -19.07% -37.03% -133.06% -1,254.80% 108.21% 66.76% - -34.29%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 5.00% -0.98% 15.97% -21.85% 8.63% 39.73% 46.32% -5.74% -202.12% - -29.78%
Return on Assets (ROA)		 4.80% 1.38% 18.91% -16.89% 12.06% 42.46% 48.15% -0.70% -182.45% - -27.62%
Return on Common Equity (ROCE)		 89.46% 0.85% -27.95% -19.07% -37.03% -133.06% -1,254.80% 108.21% 66.76% - -34.29%
Return on Equity Simple (ROE_SIMPLE)		 19.87% 0.00% -52.19% 0.00% 0.00% 0.00% 166.09% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 1.61 -0.27 12 -5.92 4.07 18 23 -0.90 -11 -20 -14
NOPAT Margin		 6.09% -1.00% 28.01% -23.56% 12.17% 46.26% 44.31% -4.82% -185.10% - -134.24%
Net Nonoperating Expense Percent (NNEP)		 0.76% 0.64% 1.30% -0.41% 1.13% 0.96% 0.88% 0.52% -2.50% - -2.11%
Return On Investment Capital (ROIC_SIMPLE)		 - 0.70% -49.36% 24.31% -22.78% 465.65% 80.85% -0.74% -10.28% -19.75% -4.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 25.82% 29.42% 18.70% 33.43% 23.79% 14.76% 18.52% 35.49% 107.78% - 104.23%
R&D to Revenue		 62.34% 72.86% 53.18% 100.23% 63.91% 38.83% 37.06% 71.40% 256.65% - 187.54%
Operating Expenses to Revenue		 88.16% 102.28% 71.89% 133.65% 87.70% 53.59% 55.57% 106.89% 364.43% - 291.77%
Earnings before Interest and Taxes (EBIT)		 3.12 -0.60 12 -8.45 4.10 18 23 -1.27 -16 -28 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.67 -2.34 10 -9.43 3.31 17 23 -1.32 -16 -28 -20
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 2.03 1.53 4.90 - 2.50
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 2.16 1.55 4.96 - 2.51
Price to Revenue (P/Rev)		 0.91 1.03 1.24 0.69 0.73 0.58 0.35 1.30 4.63 - 22.51
Price to Earnings (P/E)		 0.00 0.00 8.93 7.45 6.67 2.53 1.22 3.81 18.78 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 11.20% 13.42% 15.00% 39.54% 81.69% 26.22% 5.33% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.05 0.00 0.00 0.00 0.00 0.19 3.37 - 12.75
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 1.08 0.00 0.00 0.00 0.00 0.63 17.18 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.51 0.00 0.00 0.00 0.00 0.61 16.44 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.63 0.00 0.00 0.00 0.00 0.61 16.60 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.21 -0.20 -0.26 -0.22 -0.24 -9.30 0.11 0.01 0.00 - 0.00
Long-Term Debt to Equity		 -0.21 -0.20 -0.26 -0.22 -0.24 -9.30 0.11 0.01 0.00 - 0.00
Financial Leverage		 15.94 2.59 2.82 2.58 3.96 5.46 33.05 -3.24 -3.05 - -1.23
Leverage Ratio		 -19.67 -3.47 -3.54 -3.17 -4.82 -6.73 -42.71 3.77 3.54 - 1.33
Compound Leverage Factor		 -36.70 11.09 -4.21 -2.43 -6.81 -7.22 -44.51 0.27 3.18 - 1.23
Debt to Total Capital		 -26.07% -24.66% -34.63% -28.28% -31.34% 112.05% 10.23% 1.19% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 -26.07% -24.66% -34.63% -28.28% -31.34% 112.05% 10.23% 1.19% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 126.07% 124.66% 134.63% 128.28% 131.34% -12.05% 89.77% 98.81% 100.00% - 100.00%
Debt to EBITDA		 -0.58 -0.80 1.61 47.81 3.13 0.20 0.08 0.03 0.00 - 0.00
Net Debt to EBITDA		 10.01 14.04 -28.05 -904.84 -62.57 -4.50 -2.28 -3.74 0.00 - 0.00
Long-Term Debt to EBITDA		 -0.58 -0.80 1.61 47.81 3.13 0.20 0.08 0.03 0.00 - 0.00
Debt to NOPAT		 -0.98 8.45 0.93 1.64 0.91 0.17 0.08 0.03 0.00 - 0.00
Net Debt to NOPAT		 17.04 -148.73 -16.26 -30.97 -18.17 -3.88 -2.15 -3.65 0.00 - 0.00
Long-Term Debt to NOPAT		 -0.98 8.45 0.93 1.64 0.91 0.17 0.08 0.03 0.00 - 0.00
Altman Z-Score		 -3.63 -4.12 -3.97 -5.46 -5.76 -5.79 -6.38 -1.71 1.38 - 10.32
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.37 1.17 1.16 1.00 1.04 1.25 1.73 4.20 3.64 - 10.38
Quick Ratio		 1.34 1.14 1.13 0.98 1.01 1.21 1.63 4.08 3.54 - 10.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 86 -53 -93 -99 -95 -98 -99 -126 -110 -78 -39
Operating Cash Flow to CapEx		 -202,700.00% -8,256.77% -22,647.83% -20,363.54% -109,100.00% -24,885.00% -17,683.19% -58,344.44% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.42 0.44 0.57 0.65 0.70 0.86 1.04 0.84 0.76 - 0.16
Accounts Receivable Turnover		 45.86 5.14 16.71 51.12 43.88 42.27 19.50 60.77 45.63 - 27.32
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 19.39 22.42 29.28 30.60 36.17 42.99 50.92 53.63 48.74 - 21.42
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 7.96 71.08 21.85 7.14 8.32 8.64 18.72 6.01 8.00 - 13.36
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 7.96 71.08 21.85 7.14 8.32 8.64 18.72 6.01 8.00 - 13.36
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -235 -213 -174 -162 -135 -97 -52 -37 -36 -38 -27
Invested Capital Turnover		 -0.49 -0.42 -0.53 -0.58 -0.68 -0.89 -1.31 -1.42 -1.32 - -0.90
Increase / (Decrease) in Invested Capital		 -84 53 104 93 99 116 122 125 99 59 25
Enterprise Value (EV)		 -97 -61 5.50 -48 -20 -16 -26 26 382 - 453
Market Capitalization		 86 104 148 83 92 81 51 183 526 - 800
Book Value per Share		 ($0.77) ($0.71) ($0.47) ($0.37) ($0.30) ($0.01) $0.31 $1.49 $0.65 $0.58 $1.88
Tangible Book Value per Share		 ($0.79) ($0.73) ($0.49) ($0.39) ($0.32) ($0.03) $0.29 $1.47 $0.64 $0.58 $1.87
Total Capital		 -41 -38 -24 -24 -18 3.78 28 121 107 99 320
Total Debt		 11 9.39 8.15 6.89 5.60 4.24 2.86 1.44 0.00 0.00 0.00
Total Long-Term Debt		 11 9.39 8.15 6.89 5.60 4.24 2.86 1.44 0.00 0.00 0.00
Net Debt		 -184 -165 -142 -130 -112 -96 -77 -157 -144 -137 -347
Capital Expenditures (CapEx)		 0.01 0.27 0.12 0.10 0.02 0.08 0.12 0.03 -0.13 0.20 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -140 -147 -128 -137 -113 -79 -43 -33 -35 -40 -28
Debt-free Net Working Capital (DFNWC)		 54 27 23 0.22 4.95 22 36 125 108 97 319
Net Working Capital (NWC)		 54 27 23 0.22 4.95 22 36 125 108 97 319
Net Nonoperating Expense (NNE)		 -1.39 -1.10 -2.18 0.62 -1.67 -1.26 -0.96 -0.75 3.19 6.96 4.48
Net Nonoperating Obligations (NNO)		 -184 -165 -142 -130 -112 -96 -77 -157 -144 -137 -347
Total Depreciation and Amortization (D&A)		 -1.45 -1.74 -1.40 -0.98 -0.79 -0.37 -0.07 -0.05 -0.50 -0.21 -0.48
Debt-free, Cash-free Net Working Capital to Revenue		 -147.47% -145.72% -107.04% -114.54% -88.96% -57.27% -29.45% -23.17% -31.19% - -77.75%
Debt-free Net Working Capital to Revenue		 57.44% 26.70% 19.06% 0.19% 3.91% 15.59% 24.69% 88.87% 95.21% - 897.74%
Net Working Capital to Revenue		 57.44% 26.70% 19.06% 0.19% 3.91% 15.59% 24.69% 88.87% 95.21% - 897.74%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.04 $0.02 $0.17 ($0.08) $0.07 $0.22 $0.27 $0.00 ($0.09) ($0.33) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 80.73M 73.81M 82.03M 84.88M 85.09M 84.44M 87.12M 129.08M 165.00M 137.94M 177.27M
Adjusted Diluted Earnings per Share		 $0.04 $0.02 $0.17 ($0.08) $0.07 $0.22 $0.27 $0.00 ($0.09) ($0.33) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 80.99M 73.81M 82.63M 84.88M 85.20M 84.75M 87.15M 129.08M 165.00M 137.94M 177.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.99M 67.72M 0.00 78.12M 78.26M 80.10M 80.62M 164.91M 169.44M 170.19M 217.70M
Normalized Net Operating Profit after Tax (NOPAT)		 1.61 -0.42 12 -5.92 4.07 18 23 -0.90 -11 -20 -14
Normalized NOPAT Margin		 6.09% -1.59% 28.01% -23.56% 12.17% 46.26% 44.31% -4.82% -185.10% - -134.24%
Pre Tax Income Margin		 22.04% 7.16% 33.38% -25.81% 17.34% 49.72% 46.32% -0.49% -237.65% - -177.32%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

CytomX Therapeutics’ latest quarter shows a business that is still burning cash, but with a much smaller revenue base and a more strained balance sheet than it had a year ago. In Q4 2025, revenue dropped sharply to $663,000 from $5.96 million in Q3 and $38.1 million in Q4 2024, while the company posted a net loss of $26.5 million. That combination is a reminder that this remains a pre-profitable biotech story, with results likely driven by collaboration timing and pipeline activity rather than recurring commercial sales.

The most important takeaway for investors is the balance between liquidity and operating losses. CytomX still ended Q3 2025 with a sizable cash and investment position, but its cash balance has come down meaningfully over the last several quarters as operating losses continued. The company raised $16.6 million through common equity in Q4 2025, which helped offset the burn, but dilution remains a clear part of the funding story.

From an operational standpoint, the company has shown some ability to generate large revenue quarters in the past, but performance has been volatile. Q1 2025 produced $51.0 million in revenue and $23.5 million in net income, while Q2 and Q3 2025 were much weaker, and Q4 2025 saw revenue fall back near zero. That kind of lumpiness is common in biotech partnerships, but it also makes long-term forecasting difficult.

  • Strong liquidity cushion remains on the balance sheet. As of Q3 2025, CytomX reported $34.2 million in cash and $109.4 million in short-term investments, giving it a meaningful reserve to fund operations.
  • Q1 2025 was an exception with very strong profitability. The company posted $51.0 million in revenue and $23.5 million in net income in the first quarter, showing its platform can generate substantial collaboration revenue when milestones hit.
  • Interest and investment income continues to support results. In Q4 2025, the company generated $1.5 million in interest and investment income, which helped partially offset operating losses.
  • Operating expenses were lower in Q4 2025 than in several prior periods. Total operating expenses were $28.6 million, down from the elevated revenue-heavy quarters and below some earlier 2025 periods.
  • Working capital still appears supported by a large cash and investment base. Even after recent burn, the company had more current assets than current liabilities in Q3 2025.
  • Revenue remains highly uneven quarter to quarter. CytomX reported $50.9 million in Q1 2025, $18.7 million in Q2, $6.0 million in Q3, and just $0.7 million in Q4, making the business hard to model.
  • The company is not yet consistently profitable. Aside from Q1 2025 and some earlier periods, CytomX has generally posted losses, including a $26.5 million loss in Q4 2025 and a $14.2 million loss in Q3 2025.
  • Cash flow from operations remains negative. Q4 2025 operating cash flow was -$23.2 million, and Q3 2025 was -$15.5 million, showing the core business is still consuming cash.
  • Share dilution is continuing. CytomX raised $16.6 million through common equity in Q4 2025, and share counts have risen materially over the last year.
  • Cash and investments have declined from earlier levels. Total cash plus short-term investments at Q3 2025 were about $143.6 million, down from $196.3 million at Q1 2025 and well below the company’s mid-2024 levels.

Looking at the broader trend, CytomX is still very much a development-stage biotech company. The pattern over the last four years shows periodic spikes in revenue and earnings, likely tied to collaboration milestones, followed by renewed losses and cash burn. Investors should focus less on any single quarter and more on whether the company can continue funding its pipeline without excessive dilution while eventually creating more stable revenue visibility.

07/14/26 02:38 AM ETAI Generated. May Contain Errors.

CytomX Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CytomX Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

CytomX Therapeutics' net income appears to be on a downward trend, with a most recent value of -$17.37 million in 2025, falling from -$35.37 million in 2015. The previous period was $31.87 million in 2024. See where experts think CytomX Therapeutics is headed by visiting CytomX Therapeutics' forecast page.

CytomX Therapeutics' total operating income in 2025 was -$22.36 million, based on the following breakdown:
  • Total Gross Profit: $76.20 million
  • Total Operating Expenses: $98.57 million

Over the last 10 years, CytomX Therapeutics' total revenue changed from $7.71 million in 2015 to $76.20 million in 2025, a change of 888.1%.

CytomX Therapeutics' total liabilities were at $52.56 million at the end of 2025, a 56.6% decrease from 2024, and a 26.1% decrease since 2015.

In the past 10 years, CytomX Therapeutics' cash and equivalents has ranged from $12.67 million in 2025 to $247.58 million in 2018, and is currently $12.67 million as of their latest financial filing in 2025.

Over the last 10 years, CytomX Therapeutics' book value per share changed from 3.50 in 2015 to 0.58 in 2025, a change of -83.3%.


Related Companies

Financial statements for NASDAQ:CTMX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Your money is changing
Porter Stansberry - who warned readers about Fannie Mae in 2006, called gold in 2008, and predicted COVID-era ...
Porter & Company | Sponsoredtc pixel
The $5 company SpaceX can’t survive without
The investors who got rich on AI didn't all buy Nvidia. Some bought ASML, the company that makes the machines ...
Traders Agency | Sponsoredtc pixel
Trump Set to Unleash 219-Year-Old “Super Weapon” on U.S. Soil
Four-time U.S. Presidential advisor Jim Rickards is warning of a political move he calls 'The Trump Supremacy'...
Paradigm Press | Sponsoredtc pixel
60 years. Zero competitors.
One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...
Behind the Markets | Sponsoredtc pixel